Sequencing Treatment for Endocrine-Resistant Disease

Results from the DESTINY-Breast05 trial revealed that T-DXd was superior to T-DM1 in these patients with HER2-positive early breast cancer.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

“VIKTORIA-1 is the first study to demonstrate a statistically significant and clinically meaningful improvement in PFS with PAM inhibition in patients with PIK3CA wild-type disease, all of whom received prior CDK4/6 inhibition,” said Barbara Pistilli, MD.

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Data from the PREFER study may provide evidence for improving oncofertility counseling for premenopausal women with early breast cancer.

“This trial supports the value of a functional RAD51-based HRD assessment to refine patient selection for PARP inhibitors,” said Isabel Pimentel, MD.